PT2836491T - Forma salina de um inibidor da histona metiltransferase humana ezh2 - Google Patents

Forma salina de um inibidor da histona metiltransferase humana ezh2

Info

Publication number
PT2836491T
PT2836491T PT137749792T PT13774979T PT2836491T PT 2836491 T PT2836491 T PT 2836491T PT 137749792 T PT137749792 T PT 137749792T PT 13774979 T PT13774979 T PT 13774979T PT 2836491 T PT2836491 T PT 2836491T
Authority
PT
Portugal
Prior art keywords
salt form
histone methyltransferase
ezh2 inhibitor
human histone
methyltransferase ezh2
Prior art date
Application number
PT137749792T
Other languages
English (en)
Inventor
Wayne Kuntz Kevin
Huang Kuan-Chun
Wook Choi Hyeong
Sanders Kristen
Mathieu Steven
Chanda Arani
Fang Frank
Original Assignee
Eisai R&D Man Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Epizyme Inc filed Critical Eisai R&D Man Co Ltd
Publication of PT2836491T publication Critical patent/PT2836491T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PT137749792T 2012-04-13 2013-04-11 Forma salina de um inibidor da histona metiltransferase humana ezh2 PT2836491T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13

Publications (1)

Publication Number Publication Date
PT2836491T true PT2836491T (pt) 2017-02-08

Family

ID=49328166

Family Applications (3)

Application Number Title Priority Date Filing Date
PT191804798T PT3628670T (pt) 2012-04-13 2013-04-11 Forma salina de um inibidor de ezh2
PT137749792T PT2836491T (pt) 2012-04-13 2013-04-11 Forma salina de um inibidor da histona metiltransferase humana ezh2
PT16191716T PT3184523T (pt) 2012-04-13 2013-04-11 Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT191804798T PT3628670T (pt) 2012-04-13 2013-04-11 Forma salina de um inibidor de ezh2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT16191716T PT3184523T (pt) 2012-04-13 2013-04-11 Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico

Country Status (25)

Country Link
US (6) US9394283B2 (pt)
EP (4) EP3628670B1 (pt)
JP (3) JP6255382B2 (pt)
KR (3) KR20220123339A (pt)
CN (2) CN104603130B (pt)
AU (2) AU2013245878B2 (pt)
BR (1) BR112014025508B1 (pt)
CA (1) CA2870005C (pt)
CY (2) CY1119383T1 (pt)
DK (3) DK3184523T3 (pt)
ES (3) ES2617379T3 (pt)
HR (2) HRP20170295T1 (pt)
HU (3) HUE045353T2 (pt)
IL (4) IL296199B1 (pt)
IN (1) IN2014DN09068A (pt)
LT (2) LT2836491T (pt)
MX (1) MX362339B (pt)
NZ (1) NZ700761A (pt)
PL (3) PL3184523T3 (pt)
PT (3) PT3628670T (pt)
RS (2) RS55690B1 (pt)
RU (1) RU2658911C2 (pt)
SG (3) SG10201912109QA (pt)
SI (2) SI2836491T1 (pt)
WO (1) WO2013155317A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
KR20220123339A (ko) 2012-04-13 2022-09-06 에피자임, 인코포레이티드 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
JP6340361B2 (ja) 2012-04-13 2018-06-06 エピザイム，インコーポレイティド がんを処置するための組合せ治療
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
RU2658919C2 (ru) 2012-10-15 2018-06-26 Эпизайм, Инк. Замещенные бензольные соединения
NZ746054A (en) * 2012-10-15 2020-07-31 Epizyme Inc Methods of treating cancer
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EA030196B1 (ru) 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Ингибиторы энхансера zeste гомолога 2
RU2016104044A (ru) 2013-07-10 2017-08-15 Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед Ингибиторы усилителя zeste гомолога 2
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
FI3057962T3 (fi) 2013-10-16 2023-11-03 Epizyme Inc Hydrokloridisuolamuoto ezh2-estoon
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
EA201691079A1 (ru) 2013-12-06 2017-03-31 Эпизим, Инк. Комбинированная терапия для лечения онкологического заболевания
MX2021007651A (es) 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
DK3157928T3 (da) 2014-06-20 2019-05-20 Constellation Pharmaceuticals Inc Krystallinske former af 2-((4s)-6-(4-chlorphenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamid
MX2021007003A (es) 2014-10-16 2022-08-09 Epizyme Inc Método para tratar el cáncer.
AU2015350108B2 (en) * 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
SG11201708286PA (en) 2015-04-20 2017-11-29 Epizyme Inc Combination therapy for treating cancer
EA201890009A1 (ru) 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
US11214561B2 (en) * 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
AU2020408395A1 (en) * 2019-12-20 2022-07-07 Epizyme, Inc. Crystalline hydrobromide salt of a EZH2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
NZ277556A (en) 1993-12-27 1997-06-24 Eisai Co Ltd N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO2000018725A1 (en) 1998-09-30 2000-04-06 The Procter & Gamble Company 2-substituted ketoamides
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DK1357111T3 (da) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2003070277A1 (fr) 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antiprurigineux
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
RU2006138036A (ru) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
ATE449168T1 (de) 2004-06-01 2009-12-15 Univ North Carolina Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1891434B1 (en) 2005-06-02 2011-01-05 The University of North Carolina at Chapel Hill Purification, characterization and reconstitution of a ubiquitin e3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
BRPI0618417A2 (pt) 2005-10-19 2012-07-31 Gruenenthal Chemie novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos
BRPI0617655A2 (pt) 2005-10-21 2016-08-23 Merck & Co Inc composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
AU2006308957B2 (en) 2005-10-28 2012-04-12 The University Of North Carolina At Chapel Hill Protein demethylases comprising a JmjC domain
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2623271A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Interaction between dot1l polypeptide and calm-af10 fusion protein as a therapeutic target for leukemia
CA2650329A1 (en) 2006-05-15 2008-06-19 Irm Llc Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
CA2652634A1 (en) 2006-05-18 2007-11-29 Amphora Discovery Corporation Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
AU2009279616A1 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
WO2010111653A2 (en) 2009-03-27 2010-09-30 The Uab Research Foundation Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
CA2784899A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8637509B2 (en) * 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
MX2012012966A (es) * 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
CN103339139A (zh) 2010-12-03 2013-10-02 Epizyme股份有限公司 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
CA2867282C (en) 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
JP6340361B2 (ja) 2012-04-13 2018-06-06 エピザイム，インコーポレイティド がんを処置するための組合せ治療
KR20220123339A (ko) 2012-04-13 2022-09-06 에피자임, 인코포레이티드 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
NZ746054A (en) 2012-10-15 2020-07-31 Epizyme Inc Methods of treating cancer
FI3057962T3 (fi) 2013-10-16 2023-11-03 Epizyme Inc Hydrokloridisuolamuoto ezh2-estoon

Also Published As

Publication number Publication date
US20230140327A1 (en) 2023-05-04
CA2870005C (en) 2021-06-22
PT3184523T (pt) 2019-09-26
EP3184523B1 (en) 2019-06-19
EP3184523A1 (en) 2017-06-28
DK3628670T3 (da) 2022-12-05
IL296199A (en) 2022-11-01
US10245269B2 (en) 2019-04-02
CY1122883T1 (el) 2022-03-24
IL235045B (en) 2019-05-30
IL282732B2 (en) 2023-04-01
WO2013155317A1 (en) 2013-10-17
SG10201912109QA (en) 2020-02-27
ES2745016T3 (es) 2020-02-27
EP3628670A1 (en) 2020-04-01
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
LT2836491T (lt) 2017-03-27
PT3628670T (pt) 2022-12-02
MX362339B (es) 2019-01-11
CN104603130A (zh) 2015-05-06
PL3628670T3 (pl) 2023-02-20
IL282732B (en) 2022-12-01
JP6634058B2 (ja) 2020-01-22
CN104603130B (zh) 2018-04-27
RS59392B1 (sr) 2019-11-29
US9394283B2 (en) 2016-07-19
HRP20191653T1 (hr) 2020-02-21
ES2617379T3 (es) 2017-06-16
KR20200066380A (ko) 2020-06-09
RU2014145544A (ru) 2016-06-10
HRP20170295T1 (hr) 2017-04-21
HUE031976T2 (en) 2017-08-28
SI2836491T1 (sl) 2017-06-30
RS55690B1 (sr) 2017-07-31
EP4190777A1 (en) 2023-06-07
MX2014012380A (es) 2015-07-23
SI3184523T1 (sl) 2020-04-30
EP2836491A4 (en) 2015-09-16
RU2658911C2 (ru) 2018-06-26
US20170143729A1 (en) 2017-05-25
IL266165B (en) 2021-06-30
KR102120883B1 (ko) 2020-06-09
AU2013245878A1 (en) 2014-10-30
IL296199B1 (en) 2024-08-01
PL2836491T3 (pl) 2017-08-31
KR102438340B1 (ko) 2022-08-30
HUE045353T2 (hu) 2019-12-30
AU2018200168B2 (en) 2019-08-29
US20210137936A1 (en) 2021-05-13
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
CN108358899B (zh) 2021-07-27
JP2018002742A (ja) 2018-01-11
NZ700761A (en) 2016-09-30
US10821113B2 (en) 2020-11-03
DK3184523T3 (da) 2019-08-19
EP2836491B1 (en) 2016-12-07
LT3184523T (lt) 2020-02-10
IL282732A (en) 2021-06-30
EP3628670B1 (en) 2022-10-12
DK2836491T3 (en) 2017-03-06
US20180243316A1 (en) 2018-08-30
JP2015512942A (ja) 2015-04-30
IN2014DN09068A (pt) 2015-05-22
KR20220123339A (ko) 2022-09-06
AU2018200168A1 (en) 2018-02-01
ES2931316T3 (es) 2022-12-28
AU2013245878B2 (en) 2017-10-12
KR20150002730A (ko) 2015-01-07
CY1119383T1 (el) 2018-02-14
PL3184523T3 (pl) 2019-12-31
SG10201608577RA (en) 2016-12-29
HUE060881T2 (hu) 2023-04-28
JP6255382B2 (ja) 2017-12-27
SG11201406468YA (en) 2015-01-29
US20150065503A1 (en) 2015-03-05
US20190269692A1 (en) 2019-09-05
US9872862B2 (en) 2018-01-23
JP2018199740A (ja) 2018-12-20
US11491163B2 (en) 2022-11-08
CN108358899A (zh) 2018-08-03
IL235045A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
PL2836491T3 (pl) Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2
IL253259B (en) Inhibitors of histone demethylases
EP2701699A4 (en) INHIBITORS OF HISTONE DEACETYLASE
SI3715345T1 (sl) Priprava zaviralca lfa-1
EP2680694A4 (en) INHIBITORS OF HISTONE DEACETYLASE
AP2013006679A0 (en) Co-crystals and salts of CCR3-inhibitors
EP2914298A4 (en) Inhibition of histone metyltransferase for cardiac remission
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2683402A4 (en) VACCINATION METHOD INVOLVING HISTONE DEACETYLASE INHIBITOR
EP2939668A4 (en) PDK4 INHIBITOR AND USE THEREOF
EP2838528A4 (en) METHODS OF INHIBITING SHC-1 / P66 TO COMBAT AGING-RELATED DISEASES
PL2709584T3 (pl) Zastosowanie sensoryczne pochodnych 6-cyklopentylidenoheksanu
HK1247920A1 (zh) 組蛋白去甲基化酶抑制劑
ZA201308872B (en) Use of a dinitromethane salt
ZA201205358B (en) Use of a salt of bistetrazolylamine